Opinion on R&D in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Xolair: breathing easy over FDA approval

Xolair, developed by Genentech, Novartis and Tanox, reduces the number of attacks in severe allergic asthmatics. However prescribing restrictions, safety concerns and high cost are expected to limit sales to $593 million by 2010. The drug's best chance of success is through label extensions for pediatric use and for allergic rhinitis.<BR />

Published By Datamonitor
19 May 2003
Expert View
Expert View

Xigris: Lilly's sepsis flop misses out

Eli Lilly's Xigris sales have proved disappointing, for the year-to-date period ending February 28 2002 sales reached just $14 million, bringing total sales to $35 million since the drug's launch in late November 2001. Industry analysts had predicted sales of between $300 and $500 million in 2002, but this now seems unrealistic, so where did it all go wrong?

Published By Datamonitor
22 Mar 2002
CommentWire
CommentWire

Xenova/QLT: tackling multidrug resistance

UK biotech Xenova and its North American ally QLT will trial tariquidar for multidrug resistance in non-small cell lung cancer. As long as the results are positive, tariquidar should have a bright future: multidrug resistance is an increasingly serious problem in cancer treatment, and the developers look set to provide strong marketing support.

Published By Datamonitor
11 Jul 2002
CommentWire
CommentWire

Women's health: more HPV risk than expected

In the new survey, featuring women in their first relationship, 74% of respondents reportedly used barrier contraception. Yet nearly half developed some form of HPV infection. Companies such as Merck and Origenix, with vaccines in development for the virus, are likely to see significant revenues when their products hit the market.

Published By Datamonitor
15 Feb 2002
CommentWire
CommentWire

Verta/SciClone: new drug could limit TB spread

According to preliminary results, Russian pharma company Verta's new immune system enhancing drug may have a significant impact on TB contagion. Although the treatment regime is arduous, involving five daily injections, there could be a significant market for SCV-07 in locations where Directly Observed Treatment can be implemented.

Published By Datamonitor
01 Oct 2002
Expert View
Expert View

Use of antibiotics to drop, but frustrated patients need to be better informed of the reasons

Independent market analyst Datamonitor's latest infectious diseases report, 'Respiratory Tract Infections' suggests that the way we use antibiotics may be about to change forever. Patients are increasingly going to find that they will not be prescribed antibiotics for some respiratory tract infections (RTIs), such as a sore throats, sinusitis, or bronchitis, as often as they used to be.

Published By Datamonitor
20 Feb 2002
Expert View
Expert View

UK Arthritis Sufferers Receiving Second Best in Pain Medication

Many rheumatoid and osteoarthritis sufferers in the UK may have to settle for second best in pain medication and are being put at risk of developing serious gastrointestinal side effects (GI) according to market analysts, Datamonitor.

Published By Datamonitor
20 Feb 2002
CommentWire
CommentWire

UCB: Vimpat's efficacy in epilepsy confirmed, but other indications offer more commercial potential

New pooled data confirm Vimpat's efficacy in the adjunctive treatment of uncontrolled partial-onset seizures in adults. The drug represents a new treatment option for patients with uncontrolled epilepsy, but its inferior efficacy to Keppra is expected to limit its uptake. Nevertheless, future indication expansions in migraine and fibromyalgia may expand Vimpat's commercial potential.

Published By Datamonitor
02 Jul 2009
CommentWire
CommentWire

Tuberculosis: governments need to take action

If a TB epidemic were to occur, the impact could far outweigh the risks more publicized infections such as HIV and meningitis. The current treatments could leave many patients uncured, and there is little in the pipeline to replace them. Governments should consider subsidizing research into more effective drugs, or risk facing the consequences.

Published By Datamonitor
26 Mar 2002
ResearchWire
ResearchWire

Stroke: 7% of UK patients present within necessary time window

Published By Datamonitor
09 Jul 2001

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.